OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialActive

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

A phase 2 trial of Cemiplimab, Fianlimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.